Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Calcinosis Cutis Medication

  • Author: Julia R Nunley, MD; Chief Editor: Dirk M Elston, MD  more...
 
Updated: Feb 08, 2016
 

Medication Summary

Medical therapy generally has limited benefit. The following medications may be tried.

Next

Antacids

Class Summary

Inorganic salts can bind phosphate in the GI tract and prevent absorption.

Aluminum hydroxide (ALternaGEL, Alu-Cap, Amphojel, Dialume)

 

Aluminum hydroxide is an effective phosphate binder; it is not considered first-line therapy because of its potential for toxicity.

Magnesium oxide (Maox, Mag-ox)

 

Magnesium oxide treats magnesium deficiencies or magnesium depletion due to malnutrition, restricted diet, alcoholism, or magnesium-depleting drugs.

Previous
Next

Diphosphonates

Class Summary

These agents are used to inhibit bone turnover to lower serum calcium and phosphate levels. These agents also can absorb hydroxyapatite crystal and inhibit growth.

Etidronate disodium (Didronel)

 

Etidronate disodium reduces bone formation and does not alter renal tubular reabsorption of calcium. It does not affect hypercalcemia in patients with hyperparathyroidism.

Previous
Next

Calcium-Channel Blockers

Class Summary

Antagonism of calcium-sodium pump may diminish the intracellular calcium concentration, decreasing crystal formation.

Diltiazem hydrochloride (Cardizem)

 

Diltiazem hydrochloride is used for the management of angina, supraventricular tachycardia, and hypertension. During depolarization, it inhibits calcium ions from entering slow channels and voltage-sensitive areas of vascular smooth muscle and myocardium.

Previous
Next

Calcimimetics

Class Summary

These agents lower PTH levels by increasing sensitivity of calcium-sensing receptor on chief cell of parathyroid gland to extracellular calcium. Serum calcium also decreases.

Cinacalcet (Sensipar)

 

Cinacalcet directly lowers parathyroid hormone (PTH) levels by increasing the sensitivity of the calcium-sensing receptor on the chief cell of the parathyroid gland to extracellular calcium. This also results in concomitant serum calcium decrease.

Previous
 
 
Contributor Information and Disclosures
Author

Julia R Nunley, MD Professor, Program Director, Dermatology Residency, Department of Dermatology, Virginia Commonwealth University Medical Center

Julia R Nunley, MD is a member of the following medical societies: American Academy of Dermatology, American College of Physicians, American Society of Nephrology, International Society of Nephrology, Medical Dermatology Society, Medical Society of Virginia, National Kidney Foundation, Phi Beta Kappa, Women's Dermatologic Society

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: American Board of Dermatology<br/>Co-Editor for the text Dermatological Manifestations of Kidney Disease .

Specialty Editor Board

Richard P Vinson, MD Assistant Clinical Professor, Department of Dermatology, Texas Tech University Health Sciences Center, Paul L Foster School of Medicine; Consulting Staff, Mountain View Dermatology, PA

Richard P Vinson, MD is a member of the following medical societies: American Academy of Dermatology, Texas Medical Association, Association of Military Dermatologists, Texas Dermatological Society

Disclosure: Nothing to disclose.

Rosalie Elenitsas, MD Herman Beerman Professor of Dermatology, University of Pennsylvania School of Medicine; Director, Penn Cutaneous Pathology Services, Department of Dermatology, University of Pennsylvania Health System

Rosalie Elenitsas, MD is a member of the following medical societies: American Academy of Dermatology, American Medical Association, American Society of Dermatopathology, Pennsylvania Academy of Dermatology

Disclosure: Received royalty from Lippincott Williams Wilkins for textbook editor.

Chief Editor

Dirk M Elston, MD Professor and Chairman, Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina College of Medicine

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Additional Contributors

James W Patterson, MD Professor of Pathology and Dermatology, Director of Dermatopathology, University of Virginia Medical Center

James W Patterson, MD is a member of the following medical societies: American Academy of Dermatology, American College of Physicians, American Society of Dermatopathology, Royal Society of Medicine, Society for Investigative Dermatology, United States and Canadian Academy of Pathology

Disclosure: Nothing to disclose.

Acknowledgements

Lydia M E Jones, MD Staff Physician, Department of Dermatology, Virginia Commonwealth University

Disclosure: Nothing to disclose.

References
  1. Reiter N, El-Shabrawi L, Leinweber B, Berghold A, Aberer E. Calcinosis cutis: part I. Diagnostic pathway. J Am Acad Dermatol. 2011 Jul. 65(1):1-12; quiz 13-4. [Medline].

  2. Weinel S, Callen JP. Calcinosis cutis complicating adult-onset dermatomyositis. Arch Dermatol. 2004 Mar. 140(3):365-6. [Medline].

  3. Yun SJ, Lee JB, Kim SJ, Lee SC, Won YH, Kang HC. Calcinosis cutis universalis with joint contractures complicating juvenile dermatomyositis. Dermatology. 2006. 212(4):401-3. [Medline].

  4. Marzano AV, Kolesnikova LV, Gasparini G, Alessi E. Dystrophic calcinosis cutis in subacute lupus. Dermatology. 1999. 198(1):90-2. [Medline].

  5. Miteva L, Pramatarov K, Vassileva S. Calcinosis cutis in childhood systemic lupus erythematosus. J Eur Acad Dermatol Venereol. 2003 Sep. 17(5):611-2. [Medline].

  6. Rothe MJ, Grant-Kels JM, Rothfield NF. Extensive calcinosis cutis with systemic lupus erythematosus. Arch Dermatol. 1990 Aug. 126(8):1060-3. [Medline].

  7. Tristano AG, Villarroel JL, Rodriguez MA, Millan A. Calcinosis cutis universalis in a patient with systemic lupus erythematosus. Clin Rheumatol. 2006 Feb. 25(1):70-4. [Medline].

  8. Valenzuela A, Chung L, Casciola-Rosen L, Fiorentino D. Identification of clinical features and autoantibodies associated with calcinosis in dermatomyositis. JAMA Dermatol. 2014 Jul. 150(7):724-9. [Medline].

  9. Becuwe C, Roth B, Villedieu MH, Chouvet B, Kanitakis J, Claudy A. Milia-like idiopathic calcinosis cutis. Pediatr Dermatol. 2004 Jul-Aug. 21(4):483-5. [Medline].

  10. Eckman JA, Mutasim DF. Bullous systemic lupus erythematosus with milia and calcinosis. Cutis. 2002 Jul. 70(1):31-4. [Medline].

  11. Lee DW, Yoon DH, Lee YS, Shim SI, Cho BK. Solitary milialike idiopathic calcinosis cutis: a case unassociated with Down syndrome. J Dermatol. 1996 Jan. 23(1):53-5. [Medline].

  12. Sais G, Jucglà A, Moreno A, Peyrí J. Milia-like idiopathic calcinosis cutis and multiple connective tissue nevi in a patient with Down syndrome. J Am Acad Dermatol. 1995 Jan. 32(1):129-30. [Medline].

  13. Larralde M, Giachetti A, Kowalczuk A, D'Agostino D, Galimberti R. Calcinosis cutis following liver transplantation in a pediatric patient. Pediatr Dermatol. 2003 May-Jun. 20(3):225-8. [Medline].

  14. Lateo S, Charlton F, Hudson M, Lawrence CM. Cutaneous calcification following liver transplantation. Clin Exp Dermatol. 2005 Sep. 30(5):484-6. [Medline].

  15. Neau-Cransac M, Lepreux S, Labreze C, et al. Uncommon localization of calcinosis cutis after liver transplantation. Dermatology. 2005. 211(4):379-81. [Medline].

  16. Aksoy HM, Ozdemir R, Karaaslan O, Tiftikcioglu YO, Oruc M, Kocer U. Incidental idiopathic calcinosis cutis in a rhytidectomy patient. Dermatol Surg. 2004 Aug. 30(8):1145-7. [Medline].

  17. Campanelli A, Kaya G, Masouye I, Borradori L. Calcifying panniculitis following subcutaneous injections of nadroparin-calcium in a patient with osteomalacia. Br J Dermatol. 2005 Sep. 153(3):657-60. [Medline].

  18. Giorgini S, Martinelli C, Massi D, Lumini A, Mannucci M, Giglioli L. Iatrogenic calcinosis cutis following nadroparin injection. Int J Dermatol. 2005 Oct. 44(10):855-7. [Medline].

  19. Moss J, Syrengelas A, Antaya R, Lazova R. Calcinosis cutis: a complication of intravenous administration of calcium glucanate. J Cutan Pathol. 2006 Sep. 33 Suppl 2:60-2. [Medline].

  20. Kannan S, Ravikumar L, Mahadevan S, et al. Tumoral calcinosis with vitamin D deficiency. Saudi J Kidney Dis Transpl. 2008 Nov. 19(6):960-3. [Medline].

  21. Bhattacharya A, Prasad V, Thomas EJ, Singh B, Mittal BR. Tc-99m MDP scintigraphy in a case of idiopathic calcinosis cutis. Clin Nucl Med. 2005 Jun. 30(6):431-2. [Medline].

  22. Larsen MJ, Adcock KA, Satterlee WG. Dermal uptake of technetium-99m MDP in calcinosis cutis. Clin Nucl Med. 1985 Nov. 10(11):780-2. [Medline].

  23. Reiter N, El-Shabrawi L, Leinweber B, Berghold A, Aberer E. Calcinosis cutis: part II. Treatment options. J Am Acad Dermatol. 2011 Jul. 65(1):15-22; quiz 23-4. [Medline].

  24. Valenzuela A, Chung L. Calcinosis: pathophysiology and management. Curr Opin Rheumatol. 2015 Nov. 27 (6):542-8. [Medline].

  25. Grases F, Perello J, Isern B, Prieto RM. Study of a myo-inositol hexaphosphate-based cream to prevent dystrophic calcinosis cutis. Br J Dermatol. 2005 May. 152(5):1022-5. [Medline].

  26. Grases F, Perello J, Isern B, Prieto RM. Study of the absorption of myo-inositol hexakisphosphate (InsP6) through the skin. Biol Pharm Bull. 2005 Apr. 28(4):764-7. [Medline].

  27. Abdallah-Lotf M, Grasland A, Vinceneux P, Sigal-Grinberg M. Regression of cutis calcinosis with diltiazem in adult dermatomyositis. Eur J Dermatol. 2005 Mar-Apr. 15(2):102-4. [Medline].

  28. Palmieri GM, Sebes JI, Aelion JA, et al. Treatment of calcinosis with diltiazem. Arthritis Rheum. 1995 Nov. 38(11):1646-54. [Medline].

  29. Papadakis JT, Patrikarea A, Digenis GE, et al. Sodium thiosulfate in the treatment of tumoral calcifications in a hemodialysis patient without hyperparathyroidism. Nephron. 1996. 72(2):308-12. [Medline].

  30. Bair B, Fivenson D. A novel treatment for ulcerative calcinosis cutis. J Drugs Dermatol. 2011 Sep. 10(9):1042-4. [Medline].

  31. Robertson LP, Marshall RW, Hickling P. Treatment of cutaneous calcinosis in limited systemic sclerosis with minocycline. Ann Rheum Dis. 2003 Mar. 62(3):267-9. [Medline]. [Full Text].

  32. Velez NF, Callen JP, Vleugels RA. Calcinosis cutis: an additional therapy to consider. J Am Acad Dermatol. 2012 Jun. 66(6):1004-5; author reply 1005. [Medline].

  33. Chan AY, Li E. Electric shock wave lithotripsy (ESWL) as a pain control measure in dermatomyositis with calcinosis cutis-old method, new discovery. Clin Rheumatol. 2005 Apr. 24(2):172-3. [Medline].

  34. Sultan-Bichat N, Menard J, Perceau G, Staerman F, Bernard P, Reguiaï Z. Treatment of calcinosis cutis by extracorporeal shock-wave lithotripsy. J Am Acad Dermatol. 2012 Mar. 66(3):424-9. [Medline].

Previous
Next
 
Calcinosis cutis appearing as an indurated and nodular subcutaneous plaque in a patient with systemic lupus erythematosus.
Ulceration of a lesion of calcinosis cutis in a patient with systemic lupus erythematosus.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.